An autonomous process for selective photo-bromination and nucleophilic substitution of sartan intermediates and their analogues

Abstract

The present invention relates to fabricating a pilot-scale solar tracker continuous flow reactor for the photochemical reaction. The present invention, particularly, relates to a pilot scale process for synthesis of formula 1, which key intermediates of various intermediate of various angiotensin II receptor blockers (ARBs). More particularly, the present invention relates to an integrated continuous flow reactor platform with Bayesian optimization (BO) assisted reaction optimization that can autonomously explore the optimal conditions for photochemical bromination reaction for the synthesis of Formula 1 and Formula 2. Moreover, autonomously explored bromination conditions are seamlessly integrated with continuous flow tools to synthesize, extract, and purify the Angiotensin II receptor blocker intermediate (formula 3).

Description

[0001] AN AUTONOMOUS PROCESS FOR SELECTIVE PHOTO-BROMINATION AND NUCLEOPHILIC SUBSTITUTION OF SARTAN INTERMEDIATES AND THEIR ANALOGUES FIELD OF THE INVENTION The present invention relates to artificial intelligence-embedded continuous flow solar tracker system operates in real time for auto optimization photochemical reaction. The present invention, particularly relates to a pilot scale process for synthesis of formula 1, which key intermediates of various intermediate of various angiotensin II receptor blockers (ARBs). More particularly, the present invention relates to an artificial intelligence-embedded continuous flow solar tracker system with Bayesian optimization (BO) assisted reaction optimization that can autonomously explore the optimal conditions for photochemical bromination reaction for the synthesis of Angiotensin II receptor blocker intermediates. Moreover, autonomously explored bromination conditions are seamlessly integrated with continuous flow tools to synthesize, extract, and purify the Angiotensin II receptor blocker intermediates. Further, the present invention relates to a process for the preparation of Angiotensin II receptor blocker intermediate in a solar tracker flow reactor designed to carry out the lab scale and pilot scale process in artificial intelligence- embedded continuous flow manner. The present invention provides a continuous flow process system for the preparation of formula 1 and formula 2 or a pharmaceutically acceptable compound thereof: Wherein, R is selected from 1-benzonitrile chloro bromo, iodo, methyl, cyano, nitro, bromophenyl, functional group; R1-NH-R2is chosen from various substituted derivatives of imidazole’s, benzimidazole’s, triazole and carbazole. BACKGROUND OF THE INVENTION The World Health Organization (WHO) reports that hypertension and heart failure collectively contribute 12.8% of global mortality, Nature Reviews Cardiology, 18, 291-304 (2021). In recent years, significant strides have been made in developing hypertension medications, with nonpeptide angiotensin II receptor blockers (ARBs) emerging as a leading treatment. Commonly known as sartans, these drugs, such as Olmesartan, Irbesartan, Candesartan, and Telmisartan, share a common structural unit, the biphenyl moiety Angewandte Chemie International Edition, 57, 14476-14481 (2018). Current literature underscores the importance of benzylic bromination in synthesizing sartan family drugs. Typically, the bromination of 2-cyano-4-methyl biphenyl (formula 4) utilizes various brominating reagents, including NBS, The Journal of Organic Chemistry, 79, 223-229 (2014), DBDMH, Organic Process Research & Development, 16, 2025- 2030 (2012), and NaBrO3, Organic Process Research & Development, 24, 752-761 (2020) under the thermal, Advanced Synthesis and Catalysis, 352, 3255-3266 (2010) or a photochemical process, The Journal of Organic Chemistry, 79, 223-229 (2014) resulting in formula 1. Subsequently, a continuous flow platform is employed for nucleophilic substitution reactions, yielding the intermediate (formula 3). However, traditional sartan intermediate manufacturing often relies on a non-continuous or "batch" process distributed across multiple sites. This batch approach presents various limitations, including low space-time yield (STY), prolonged production timelines (3-7 days), modest yields, lack of selectivity, and complex workup. These constraints contribute to elevated costs associated with the rapid synthesis of diverse molecular structures, potentially causing disruptions in the supply chain. The Journal of Organic Chemistry, 79, 223-229 (2014); Advanced Synthesis and Catalysis, 352, 3255-3266 (2010). In photochemical bromination, factors such as mixing efficiency, light intensity, and reaction time impact product selectivity, ACS Central Science, 5, 109-115 (2019). A comprehensive study of synergies among key factors is essential for understanding, Chemical Reviews, 122, 2752-2906 (2022). The current labor-intensive optimization process hinders progress in photochemical chemistry, ACS Central Science, 7, 1126-1134 (2021). Solar-light-mediated bromination reactions face challenges from natural hindrances like climate conditions, Green Chemistry, 24, 4794-4799 (2022). Continuous flow processes, coupled with automation and AI technology, are extensively utilized in pharmaceuticals, fine chemicals, and petrochemicals for optimizing reaction outcomes, Chemical Engineering Journal 453, 139707 (2023); Nature Chemistry, 13, 451-457 (2021). In photochemical bromination reactions, advanced sensors and automation software enable real-time optimization, reducing the need for manual intervention. Automated flow chemistry is an efficient replacement for labor-intensive optimization processes, paving the way for exploring new synthetic pathways. The conventional controlled light system for benzylic bromination is hindered by high costs and low efficiency, RSC Advances, 4, 37419-37422 (2014). An alternative approach using solar- energy-conversion technologies is proposed for emission-free chemical production, Chemical Society Reviews, 48, 1862-1864 (2019). The following discussion presents a review of the existing literature pertaining to the photochemical bromination under conventional controlled light system, rendering an overview of the prior art references in this field. These references serve as a testament to the extensive research conducted in this area and provide valuable insights into the techniques and methodologies employed in the photochemically induced bromination. The above information disclosed is only for the enhancement of understanding of the background of the invention. Thus, keeping in view the drawbacks of the hitherto reported prior arts, challenged with major issues particularly the high costs, low and mixing efficiency, light intensity, and reaction time which on impact product selectivity. In view of above, despite challenges like climate interference in solar-light-mediated reactions, present invention introduces a novel solution employing a artificial intelligence-embedded continuous flow solar tracker system to ensure consistent sunlight for the reaction and auto optimization preparation of Angiotensin II receptor blocker intermediate, which obviates the drawbacks of the hitherto known prior art. The present invention addresses the challenges mentioned above by exploiting the continuous flow technology to prepare a photo-flow reactor platform that incorporates the auto-optimizer for rapid screening of bromination. Also, the invention exploits continuous flow technology merger with a solar panel tracker to facilitate the large-scale bromination of formula 3a to the synthesis substituted benzyl bromide [formula 1a] and further preparation of Angiotensin II receptor blocker intermediate (formula 2). Furthermore, present invention extends to the integration of autonomously explored bromination conditions with continuous flow tools for the synthesis, extraction, and purification of the Angiotensin II receptor blocker intermediate (formula 3). OBJECTIVE OF THE INVENTION The main objective of the present invention is artificial intelligence-embedded continuous flow solar tracker system operates in real time for auto optimization preparation of Angiotensin II receptor blocker intermediate [ Formula 2]. Another objective of the present invention, wherein artificial intelligence-embedded continuous flow solar tracker platform with Bayesian optimization (BO) assisted reaction optimization that can autonomously explore the optimal conditions for photochemical bromination reaction to synthesize substituted benzyl bromide [formula 1]. Another objective of the present invention, wherein to control and optimize parameters to incorporate the merger of the solar tracker with a continuous photo flow process for the lab-scale and pilot-scale synthesis of substituted benzyl bromide [formula 1]. Yet another objective of the present invention, wherein artificial intelligence-embedded continuous flow solar tracker induced bromination conditions are seamlessly integrated with continuous flow tools to synthesize, extract, and purify the Angiotensin II receptor blocker intermediate (formula 2). Yet another objective of the present invention, wherein artificial intelligence-embedded continuous flow solar tracker system, operates in real time for auto optimization preparation of Angiotensin II receptor blocker intermediate [Formula 2] or a pharmaceutically acceptable compounds comprising: a. plurality of pumps [1] provided for the continuous flow of reactant connected with the plurality of holders; b. flow rate controller [1’] to maintain flow rate of the reactant; c. tubular photo reactor [2] exposed to light with a coiled capillary reactor; d. cooling system [3] to cool the photo reactor; e. power supplier [4] to provide a variation of light; f. In-line IR [5] for analysis purpose; g. auto collector [6] to collect desired product; h. central computer system [7] configured to operate the pump [1] flow rate, the photo reactor [2], the power supplier [4], and the auto collector [6]; i. extractor [9] for inline extraction; and j. separator

[0010] to removing inorganic impurities made by hydrophobic membrane has an average pore size of 0.25-0.45 mm. Yet another objective of the present invention, wherein, the outer diameter [OD] of tubular photo reactor [2] is in the range of 1 / 16 to 1 / 2mm, inner diameter [ID] is in the range of 1 mm to 5 mm, length in the range of 1 m to 100m, and volume in the range of 1ml to 1000 ml to provide continuous flow with the help of artificial intelligence. Yet another objective of the present invention, wherein for covering the photo reactor [2] with film [8] made from a material allowing the transmittance of blue light selected from glass, perfluoroalkoxy [PFA], polyethylene, polypropylene, nylon and polyetheretherketone (PEEK); Yet another objective of the present invention, wherein power supplier [4] to provide a variation of light selected from the blue, green, red, white, high-pressure, low-pressure, medium-pressure Hg lamp thereof. Yet another objective of the present invention, wherein auto optimization artificial intelligence- based continuous flow process for the preparation of Angiotensin II receptor blocker intermediate (formula 2) by artificial intelligence-embedded continuous flow solar tracker system comprising the reaction of substituted benzyl bromide[formula 1] (0.1-1 M), and substituted secondary amines [formula 4) in polar solvent. Yet another objective of the present invention, wherein the substituted benzyl bromide [Formula 1] is prepared by bromination reaction of substituted phenylmethane [Formula 3] with N- Bromosuccinimide [NBS] in artificial intelligence-embedded continuous flow solar tracker system to get compound of formula 1. Yet another objective of the present invention, wherein lab scale preparation of substituted benzyl bromide [Formula 1] in artificial intelligence-embedded continuous flow solar tracker system and pilot scale preparation of substituted benzyl bromide [formula 1] with 93-94 % yield in continuous flow process solar tracker system consisting of solar tractor continuous flow reaction platform [figure 7]. These objectives of the present invention, as well as other objectives related thereto, will be readily apparent post consideration of the description of the invention, together with reference to the contents of the Figures of the drawings. Additional objects, advantages and other novel features of the invention will appear as the description proceeds and in part will become apparent to those skilled in the art upon examination of the following. The disclosure highlights the objectives of the invention, its distinctive features, and various innovations. To gain a better grasp of the invention, its operational benefits, and the specific goals it achieves, referring to the accompanying drawings and descriptive content, which showcase preferred embodiments of the invention, would be beneficial. SUMMARY OF THE INVENTION Additional features and embodiments of the present disclosure will be better understood through the techniques and other aspects of the disclosure. Other embodiments of the invention are described in detail herein and are considered a part of the claimed disclosure. This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description section. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter. The following is a condensed description of the disclosure to give the reader with a basic understanding. Its main goal is to present some of the principles described in this document in a simpler version as a prologue to the more extensive exposition that follows. The present invention, and in accordance with main aspect of the present invention provides an artificial intelligence-embedded continuous flow solar tracker system operates in real time for auto optimization preparation of Angiotensin II receptor blocker intermediate [Formula 2] or a pharmaceutically acceptable compounds comprising: a. plurality of pumps [1] provided for the continuous flow of reactant connected with the plurality of holders; b. flow rate controller [1’] to maintain flow rate of the reactant; c. tubular photo reactor [2] exposed to light with a coiled capillary reactor; d. cooling system [3] to cool the photo reactor; e. power supplier [4] to provide a variation of light; f. In-line IR [5] for analysis purpose; g. auto collector [6] to collect desired product; h. central computer system [7] configured to operate the pump [1] flow rate, the photo reactor [2], the power supplier [4], and the auto collector [6]; i. extractor [9] for inline extraction; and j. separator

[0010] to removing inorganic impurities made by hydrophobic membrane has an average pore size of 0.25-0.45 mm. wherein, the outer diameter [OD] of tubular photo reactor [2] is in the range of 1 / 16 to 1 / 2mm, inner diameter [ID] is in the range of 1 mm to 5 mm, length in the range of 1 m to 100m, and volume in the range of 1ml to 1000 ml to provide continuous flow with the help of artificial intelligence; wherein the means for covering the photo reactor [2] with film [8] made from a material allowing the transmittance of blue light selected from glass, perfluoroalkoxy [PFA], polyethylene, polypropylene, nylon and polyetheretherketone (PEEK); Wherein, power supplier [4] to provide a variation of light selected from the blue, green, red, white, high-pressure, low-pressure, medium-pressure Hg lamp thereof. In another aspect of the invention, the present invention discloses an auto optimization artificial intelligence-based continuous flow process for the preparation of Angiotensin II receptor blocker intermediate (formula 2) by artificial intelligence-embedded continuous flow solar tracker system, wherein process of preparation of formula 2 comprising the step of:- wherein, R1-N-R2 is selected from various substituted derivatives of imidazole’s, benzimidazole’s, triazole and carbazole. 20 (a) pumping a solution of reactants [substituted benzyl bromide (formula 1)] (0.1-1 M), and [substituted secondary amines (formula 4)] (0.1-1 M) in a polar solvent into a stainless-steel cartridge bed reactor [7.0 ml - 1L] filled with base at a temperature in the range of 30 to 100 °C and at a pressure in the range of 1-15 bar; maintaining the reaction mixture in reactor for the time period in the range of 0.6-12.5 minutes yielded the compound of formula 2;

[0002] Sc eme- In another aspect of the present invention, wherein the [substituted secondary amines (formula 4)] selected from the group consisting of 2-butyl-4-chloro-1H-imidazole-5-carbaldehyde (4a), (2- butyl-4-chloro-1H-imidazol-5-yl)methanol (4b), methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H- imidazole-5-carboxylate (4c), diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate(4d), 1H- imidazole (4e), 2-methyl-1H-imidazole(4f), 2-phenyl-1H-imidazole(4g), methyl 2-ethoxy-1H- benzo[d]imidazole-7-carboxylate(4h), ethyl 2-ethoxy-1H-benzo[d]imidazole-7-carboxylate(4i), 1H-benzo[d]imidazole--methane (4j), 2-phenyl-1H-benzo[d]imidazole (4k), 1H- benzo[d]imidazol-2-amine(4l), 1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazole(4m), 2- butyl-1,3-diazaspiro[4.4]non-1-en-4-one(4n), 1H-1,2,4-triazole(4o), 9H-carbazole--methane(4p). Yet another aspect of the present invention, wherein polar solvent selected from the group consisting of acetone, acetonitrile, dimethylformamide (DMF), dimelthylsulfoxide (DMSO), isopropanol, and methanol and mixtures thereof and base selected from the group consisting of K2CO3, Na2CO3, KOH, and Amberlyst-15 hydroxide. Yet another aspect of the present invention, wherein compounds of Formula 2 selected from the group consisting of from 4'-((2-Butyl-4-chloro-5-formyl-1H-imidazol-1-yl) methyl)-[1,1'- biphenyl]-2-carbonitrile (Losartan intermediate) (2a), 4'-((2-Butyl-4-chloro-5-(hydroxymethyl)- 1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (Losartan intermediate) (2b), Ethyl 1- ((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5- carboxylate (Olmesartan intermediate) (2c), Diethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2- propyl-1H-imidazole-4,5-dicarboxylate (Olmesartan intermediate) (2d), 4'-((Imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2e), 4'-((2-Methyl imidazol-1-yl) methyl)-[1,1'-biphenyl]- 2-carbonitrile (2f), 4'-((2-Phenyl imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2g), Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2-ethoxy benzimidazole-7-carboxylate (candesartan intermediate) (2h), Ethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2-ethoxy benzimidazole-7-carboxylate (candesartan intermediate) (2i), 4'-((Benzimidazol-1-yl) methyl)- [1,1'-biphenyl]-2-carbonitrile (2j), 4'-((2-Phenyl benzimidazol-1-yl) methyl)-[1,1'-biphenyl]-2- carbonitrile (2k), 4'-((2-Amino benzimidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2l), 4'- ((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl) methyl)-[1,1'-biphenyl]-2- carbonitrile (Telmisartan intermediate) (2m), 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3- yl)methyl)-[1,1'-biphenyl]-2-carbonitrile (Irbesartan precursor) (2n), 4'-((1,2,4-Triazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2o), 4'-((Carbazol-9-yl) methyl)-[1,1'-biphenyl]-2- carbonitrile (2p). Yet another aspect of the present invention, wherein the substituted benzyl bromide [Formula 1] prepared by bromination reaction of substituted phenylmethane [Formula 3] with N- Bromosuccinimide [NBS] in artificial intelligence-embedded continuous flow solar tracker system to get compound of formula 1 comprising the step of:- a) pumping a solution of reactants of formula 3 (0.1-1 M), and NBS (0.1-1 M) in a polar aprotic solvent into a PFA tubular photo reactor [2], Figure-1] exposed to light selected from the blue, green, red, white, high-pressure, low-pressure, medium-pressure Hg lamp thereof; b) maintaining the reaction mixture in PFA tubular photo reactor [2], Figure-1] for the time period in the range of 0.6-12.5 minutes under pressure in the range of 1-10 bar; c) inline extraction [9] and separation by separator

[0010] removing inorganic impurities to obtain compound of formula 1; Still another aspect of the present invention, wherein substituted phenylmethane (formula 3) selected from the group consisting of 1-benzonitrile, chloro, bromo, iodo, methyl, cyano, nitro, bromophenyl and polar aprotic solvent selected from the group consisting of MeCN, dichloromethane, dichloroethane, aromatic hydrocarbons, cyclic hydrocarbons, THF, Ethyl Acetate, and mixtures thereof. Still another aspect of the present invention, wherein represented compound of substituted benzyl bromide (formula 1) selected from 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile (formula 1a), 1-(bromomethyl)-4-iodobenzene (1b), 1-bromo-4-(bromomethyl)benzene (1c), 1-(bromomethyl)- 4-chlorobenzene (1d), 4-(bromomethyl) benzonitrile (1e), 1-(bromomethyl)-4-nitrobenzene (1f), 1-(bromomethyl)-3-iodobenzene (1g), 1-(bromomethyl)-3-iodo-5-methylbenzene (1h), 1- (bromomethyl)-3,5-dimethylbenzene (1i), 1-(bromomethyl)-2-iodobenzene (1j), 2- (bromomethyl)benzonitrile (1k), 1-(bromomethyl)-2-nitrobenzene (1l), 2-bromo-1- (bromomethyl)-3-methylbenzene (1m), 1-bromo-2-(bromomethyl)naphthalene (1n), 9-bromo- 9H-fluorene (1o). Still another aspect of the present invention, wherein lab scale preparation of substituted benzyl bromide [Formula 1] in artificial intelligence-embedded continuous flow solar tracker system and pilot scale preparation of substituted benzyl bromide [formula 1] with 93-94 % yield in continuous flow process solar tracker system consisting of (figure 7): i. a plurality of holders [1] for holding particular reactant; ii. a plurality of pumps [2] provided for the continuous flow of reactant connected with the plurality of holders; iii. a flow rate controller to maintain flow rate of the reactant; iv. a plurality of syringes [3] to inject the reactants from the holder [1]; v. a solenoid valve [4] coupled with a light-dependent resistor (LDR) micro controller system [5] to control the direction of reagent flow according to the light intensity; vi. a panel reactor [6] includes A solar light source [7], and A reactor tubes [8]; vii. a solar light source [7] displayed at the one end for transporting the reactants [8]; viii. a reactor tubes [8] displayed at another end for Product collector

[0014] to collecting the product; ix. a panel switch

[0010] ; x. a stepper motor speed

[0012] programmed to track the sun’s trajectory; and xi. a computer program

[0011] configured to control the stepper motor speed

[0012] , and solar panel reactor

[0013] movement. BRIEF DESCRIPTION OF THE DRAWINGS To complete the description and in order to provide for a better understanding of the present invention, a set of drawings is provided. The drawings form an integral part of the description and illustrate an embodiment of the present invention, which should not be interpreted as restricting the scope of the invention, but just as an example of how the invention can be carried out. The drawings comprise the following figures: Figure 1 illustrates the Artificial intelligence-based continuous flow photo-reactor platform for auto-optimizing the bromination reaction.; (a) pumps; (b) assembled 1mL photoreactor with cooling under artificial blue light; (c) power supply is used to vary the power of blue light ; (d) Assembled capillary reactor over the solar tracker; (e) ReactIR for in-line FT-IR analysis and after stabilized spectral data obtained by in-line FT-IR; (f) Auto-collector is the collect sample in steady state according to experiments; (g) Central system controlled all pumps, light intensity via power supply, auto-collector and analysis of IR data continuous and apply algorithm for maximum yields. Figure 2 illustrates In-line IR background analysis of formula 3a, NBS, 1a + NBS after reaction, and formula 1a in ACN. Figure 3 illustrates 3D graph of the relation between voltage (V), current (Amp), and blue light intensity (W). Figure 4 illustrates Photochemical bromination reaction various parameter auto-optimized out-put data corresponding to (a, b) of 0.25 M & (c, d) of 0.5 M concentrations of formula 3a, respectively. Figure 5 illustrates the integrated continuous flow platform for the synthesis of formula 1. Integrated continuous flow for the bromination reaction; reaction condition: formula 3 (0.25 M in EA), NBS (0.253 M in EA: ACN (4:1), PFA tubing (5.0 mL), under 60W blue light, temp.25 °C ± 5 °C yields are based on the isolated yield. Figure 6 illustrates Lab-scale solar tractor continuous flow reaction optimized platform for the synthesis of formula 1a. Figure 7 illustrates Pilot scale solar tractor continuous flow reaction platform synthesis of formula 1a. Pilot scale Figure 8 illustrates Fabrication of the pilot-scale solar tractor reactor. Figure 9 illustrates correlation of yields (%) v / s time period (h) Figure 10 illustrates the integrated continuous flow platform for the synthesis of various angiotensin II receptor blockers (formula 2); Reaction condition: Step 1: formula 3a in (0.25 M) ACN, NBS in (0.253 M) EA: ACN (4:1), PFA tubing (5.0 mL), 60W blue light; Step 2: 0.136 M of Formula 4 in DMF, a 100 mL SS packed bed, residence time of 3.4 min, temp.25 °C ± 5 °C, yields are based on the isolated yield. LIST OF ABBREVIATIONS ACN = Acetonitrile BPR = Back pressure regulator DMF = Dimethyl formamide DBDMH = 1,3-dibromo-5,5-dimethyl hydantoin Br2 = Molecular Bromine HPLC = High-pressure Liquid chromatography HRMS = High-resolution mass spectroscopy id = Inner Diameter IR = Infra-red LC-MS = Liquid chromatography-mass spectroscopy KOH = Potassium Hydroxide K2CO3 = Potassium carbonate Na2CO3= Sodium carbonate NaBrO3 = Sodium bromates NBS = N-bromosuccinimide NMR = Nuclear Magnetic resonance od = Outer Diameter PFA = Perfluoroalkoxy alkane PTFE = Polytetrafluoroethylene SS = Stainless Steel TLC = Thin layer chromatography tR = Residence time UV = Ultra-Violet DETAILED DESCRIPTION OF THE INVENTION The following description is not to be taken in a limiting sense but is given solely for the purpose of describing the broad principles of the invention. Embodiments of the invention will be described by way of example, with reference to the above-mentioned drawings showing elements and results according to the present invention. The foregoing detailed description of the disclosure is elaborated to provide a clear understanding to the person who is skilled in the art. Additional features, embodiments and advantages of the invention will be described hereinafter which form the subject of the claims of the disclosure, However, the set forth disclosure provide in the specification will best be understood in conjunction with the appended claims and figures as provide heretofore. It should be appreciated by those skilled in the art that the conception and specific embodiment disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present disclosure. It should also be realized by those skilled in the art that such equivalent processes do not depart from the spirit and scope of the disclosure as set forth in the appended claims. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the figures, can be arranged, substituted, combined, and designed in various configurations, all of which are explicitly contemplated and make part of this disclosure. While the invention has been disclosed with reference to certain embodiments, it will be understood by those skilled in the art that various changes may be made, and equivalents may be substituted without departing from the scope of the invention. In addition, many modifications may be made to adapt to a particular situation or material to the teachings of the invention without departing from its scope. Throughout the specification and claims, the following terms take the meanings explicitly associated herein unless the context clearly dictates otherwise. The meaning of "a", "an", and "the" include plural references. The meaning of "in" includes "in" and "on." Referring to the figures, like numbers indicate like parts throughout the views. Additionally, a reference to the singular includes a reference to the plural unless otherwise stated or inconsistent with the disclosure herein. The present invention relates to artificial intelligence-embedded continuous flow solar tracker system operates in real time for auto optimization preparation of Angiotensin II receptor blocker intermediate. More particularly, the present invention relates to the present invention relates to an artificial intelligence-embedded continuous flow solar tracker system with Bayesian optimization (BO) assisted reaction optimization that can autonomously explore the optimal conditions for photochemical bromination reaction for the synthesis of Angiotensin II receptor blocker intermediates. Moreover, autonomously explored bromination conditions are seamlessly integrated with continuous flow tools to synthesize, extract, and purify the Angiotensin II receptor blocker intermediates. Process for the preparation of Angiotensin II receptor blocker intermediate in a solar tracker flow reactor designed to carry out the lab scale and pilot scale process in artificial intelligence-embedded continuous flow manner. In an embodiment of the present invention, wherein merger of a solar tracker and continuous flow reactor to prepare Formula 1 and Formula 2. In an embodiment of the present invention, wherein preparation of Angiotensin II receptor blocker intermediate (formula 2) by artificial intelligence-embedded continuous flow solar tracker system occurred by the reaction of substituted benzyl bromide (formula 1)] (0.1-1 M), and [substituted secondary amines ( formula 4) ] (0.1-1 M) in a polar solvent into a stainless-steel cartridge bed reactor [7.0 ml - 1L] filled with base at a temperature in the range of 30 to 100 °C and at a pressure in the range of 1-15 bar; maintaining the reaction mixture in reactor for the time period in the range of 0.6-12.5 minutes yielded the compound of Angiotensin II receptor blocker intermediate (formula 2) Scheme-2. Scheme-2 In an another embodiment of the present invention, wherein substituted benzyl bromide [Formula 1] is prepared by bromination reaction of substituted phenylmethane [Formula 3] with N- Bromosuccinimide [NBS] in artificial intelligence-embedded continuous flow solar tracker system [ Scheme-3]. In an embodiment of the present invention, wherein artificial intelligence-embedded continuous flow solar tracker system operates in real time for auto optimization preparation of Angiotensin II receptor blocker intermediate [ Formula 2] or a pharmaceutically acceptable compounds comprising: a. plurality of pumps [1] provided for the continuous flow of reactant connected with the plurality of holders; b. flow rate controller [1’] to maintain flow rate of the reactant; c. photo reactor [2] exposed to light with a coiled capillary reactor; d. cooling system [3] to cool the photo reactor; e. power supplier [4] to provide a variation of light; f. In-line IR [5] for analysis purpose; g. auto collector [6] to collect desired product; h. central computer system [7] configured to operate the pump [1] flow rate, the photo reactor [2], the power supplier [4], and the auto collector [6]; i. extractor [9] for inline extraction; and j. separator

[0010] to removing inorganic impurities made by hydrophobic membrane has an average pore size of 0.25-0.45 mm. In an embodiment of the present invention, wherein the photo reactor [2] tubing outer diameter [OD] in the range of 1 / 16 to 1 / 2mm; inner diameter [ID] in the range of 1 mm to 5 mm, length in the range of 1 m to 100 m, and volume in the range of 1ml to 1000 ml to provide continuous flow with the help of artificial intelligence; In an embodiment of the present invention, wherein the means for covering the photo reactor [2] with film [8] made from a material allowing the transmittance of blue light selected from glass, perfluoroalkoxy [PFA], polyethylene, polypropylene, nylon and polyetheretherketone (PEEK); In an embodiment of the present invention, wherein power supplier [4] to provide a variation of light selected from the blue, green, red, white, high-pressure, low-pressure, medium-pressure Hg lamp thereof. In an embodiment of the present invention, wherein an auto optimization artificial intelligence- based continuous flow process for the preparation of Angiotensin II receptor blocker intermediate (formula 2) by artificial intelligence-embedded continuous flow solar tracker system, wherein process of preparation of formula 2 comprising the step of:- wherein, R1-N-R2 is selected derivatives of imidazole’s, benzimidazole’s, triazole and carbazole. Scheme-1 (a) pumping a solution of reactants [substituted benzyl bromide (formula 1)] (0.1-1 M), and [substituted secondary amines (formula 4)] (0.1-1 M) in a polar solvent into a stainless-steel cartridge bed reactor [7.0 ml - 1L] filled with base at a temperature in the range of 30 to 100 °C and at a pressure in the range of 1-15 bar; maintaining the reaction mixture in reactor for the time period in the range of 0.6-12.5 minutes yielded the compound of formula 2;

[0003] In an embodiment of the present invention, wherein the formula 4 [substituted secondary amines] selected from the group consisting of 2-butyl-4-chloro-1H-imidazole-5-carbaldehyde (4a), (2- butyl-4-chloro-1H-imidazol-5-yl)methanol (4b), methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1H- imidazole-5-carboxylate (4c), diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate(4d), 1H- imidazole (4e), 2-methyl-1H-imidazole(4f), 2-phenyl-1H-imidazole(4g), methyl 2-ethoxy-1H- benzo[d]imidazole-7-carboxylate(4h), ethyl 2-ethoxy-1H-benzo[d]imidazole-7-carboxylate(4i), 1H-benzo[d]imidazole--methane (4j), 2-phenyl-1H-benzo[d]imidazole (4k), 1H- benzo[d]imidazol-2-amine(4l), 1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazole(4m), 2- butyl-1,3-diazaspiro[4.4]non-1-en-4-one(4n), 1H-1,2,4-triazole(4o), 9H-carbazole--methane(4p). In an embodiment of the present invention, wherein polar solvent selected from the group consisting of acetone, acetonitrile, dimethylformamide (DMF), dimelthylsulfoxide (DMSO), isopropanol, and methanol and mixtures thereof and base selected from the group consisting of K2CO3, Na2CO3, KOH, and Amberlyst-15 hydroxide. In an embodiment of the present invention, wherein compounds of Angiotensin II receptor blocker intermediate (formula 2) is selected from the group consisting of from 4'-((2-Butyl-4-chloro-5- formyl-1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (Losartan intermediate) (2a), 4'- ((2-Butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (Losartan intermediate) (2b), Ethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-4-(2- hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate (Olmesartan intermediate) (2c), Diethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2-propyl-1H-imidazole-4,5-dicarboxylate (Olmesartan intermediate) (2d), 4'-((Imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2e), 4'- ((2-Methyl imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2f), 4'-((2-Phenyl imidazol-1- yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2g), Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)- 2-ethoxy benzimidazole-7-carboxylate (candesartan intermediate) (2h), Ethyl 1-((2'-cyano-[1,1'- biphenyl]-4-yl) methyl)-2-ethoxy benzimidazole-7-carboxylate (candesartan intermediate) (2i), 4'- ((Benzimidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2j), 4'-((2-Phenyl benzimidazol-1- yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2k), 4'-((2-Amino benzimidazol-1-yl) methyl)-[1,1'- biphenyl]-2-carbonitrile (2l), 4'-((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'- yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (Telmisartan intermediate) (2m), 4'-((2-butyl-4-oxo- 1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile (Irbesartan precursor) (2n), 4'-((1,2,4-Triazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2o), 4'-((Carbazol-9-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2p). In an embodiment of the present invention, wherein the substituted benzyl bromide [Formula 1] is prepared by bromination reaction of substituted phenylmethane [Formula 3] with N- Bromosuccinimide [NBS] in artificial intelligence-embedded continuous flow solar tracker system to get compound of formula 1 comprising the step of: - a) pumping a solution of reactants of formula 3 (0.1-1 M), and NBS (0.1-1 M) in a polar aprotic solvent into a PFA tubular photo reactor [2, Figure-1] exposed to light selected from the blue, green, red, white, high-pressure, low-pressure, medium-pressure Hg lamp thereof; b) maintaining the reaction mixture in PFA tubular photo reactor [2, Figure-1] for the time period in the range of 0.6-12.5 minutes under pressure in the range of 1-10 bar; c) inline extraction [9] and separation by separator

[0010] removing inorganic impurities to obtain compound of formula 1; In an embodiment of the present invention, wherein substituted phenylmethane [Formula 3] selected from the group consisting of 1-benzonitrile, chloro, bromo, iodo, methyl, cyano, nitro, bromophenyl and polar aprotic solvent selected from the group consisting of MeCN, dichloromethane, dichloroethane, aromatic hydrocarbons, cyclic hydrocarbons, THF, Ethyl Acetate, and mixtures thereof. In an embodiment of the present invention, wherein represented compound of substituted benzyl bromide (formula 1) is selected from 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile (formula 1a), 1-(bromomethyl)-4-iodobenzene (1b), 1-bromo-4-(bromomethyl)benzene (1c), 1- (bromomethyl)-4-chlorobenzene (1d), 4-(bromomethyl) benzonitrile (1e), 1-(bromomethyl)-4- nitrobenzene (1f), 1-(bromomethyl)-3-iodobenzene (1g), 1-(bromomethyl)-3-iodo-5- methylbenzene (1h), 1-(bromomethyl)-3,5-dimethylbenzene (1i), 1-(bromomethyl)-2- iodobenzene (1j), 2-(bromomethyl)benzonitrile (1k), 1-(bromomethyl)-2-nitrobenzene (1l), 2- bromo-1-(bromomethyl)-3-methylbenzene (1m), 1-bromo-2-(bromomethyl)naphthalene (1n), 9- bromo-9H-fluorene (1o). In an embodiment of the present invention, wherein lab scale preparation of substituted benzyl bromide [Formula 1] in artificial intelligence-embedded continuous flow solar tracker system and pilot scale preparation of substituted benzyl bromide [formula 1] with 93-94 % yield in continuous flow process solar tracker comprising (figure 7): i. a plurality of holders [1] for holding particular reactant; ii. a plurality of pumps [2] provided for the continuous flow of reactant connected with the plurality of holders; iii. a flow rate controller to maintain flow rate of the reactant; iv. a plurality of syringes [3] to inject the reactants from the holder [1]; v. a solenoid valve [4] coupled with a light-dependent resistor (LDR) micro controller system [5] to control the direction of reagent flow according to the light intensity; vi. a panel reactor [6] includes A solar light source [7], and A reactor tubes [8]; vii. a solar light source [7] displayed at the one end for transporting the reactants [8]; viii. a reactor tubes [8] displayed at another end for Product collector

[0014] to collecting the product; ix. a panel switch

[0010] ; x. a stepper motor speed

[0012] programmed to track the sun’s trajectory; and xi. a computer program

[0011] configured to control the stepper motor speed

[0012] , and solar panel reactor

[0013] movement. In an embodiment of the present invention, wherein processes described in the prior arts are mainly batch processes and have significant disadvantages. In contrast to the prior art processes, the present invention provides efficient, improved, simple, economical, and scalable new processes by amalgamating solar and continuous flow platforms to enable the selective generation of Formula 1. Further extended present invention for the synthesis of intermediates for various angiotensin II receptor blockers such as Losartan, Olmesartan, Candesartan, Irbesartan, and Telmisartan and thereof (formula 2). The main objective of the present invention is to provide a controlled process using a system that merges a solar tracker and a photo-flow reactor for the large- scale synthesis of Formula 1a. As used herein, the modifier “about” should be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the expression “from about 1 to about 4” also discloses the range “from 1 to 4”. When used to modify a single number, the term “about” may refer to ±10%, may cover a range of 9% to 11%, and “about 1” means from 0.9-1.1. As used herein, the term “reduced pressure” refers to a pressure that is less than atmospheric pressure. For example, the reduced pressure is about 1mbar to about 50 mbar. As used herein, the term “pump” refers to a device that moves fluids, or sometimes slurries, by mechanical action. General procedure reactor setup for photo flow reactor & manual optimization of photo- flow bromination. The experimental setup involved filling a syringe with a two-stock solution comprising 2-cyano- 4-methyl biphenyl (Formula 3a) and N-bromosuccinimide (NBS). This syringe was connected to PFA (perfluoroalkoxy) tubing. To maintain a stoichiometric ratio, the solutions were infused through a T-mixer at identical flow rates. The mixture then flowed through a PFA tubing with specified dimensions {outer diameter (od) = 1.58 mm, inner diameter (id) = 1 mm, length (l) = 1.3 m, volume (v) = 1.0 mL}. The tubing reactor, wrapped within helical grooves around a cylindrical frame, was cooled by circulating water while being irradiated by a blue light (30W). After testing various conditions, it was determined that a flow rate of 18 mL / h for each solution, combined with a blue light (30W) and a residence time of 1.67 minutes at room temperature, yielded the best result. This optimized setup resulted in a 91% yield of 4'-bromomethyl-2-cyanobiphenyl (Formula 1a), as indicated in (Table 1, entry 4). Table 1: Manual optimization of photo-flow bromination.

[0004] Flow rate (mL / h)Residence timeLight source Yields Entry A B (min) (W) (%) 1 12 12 2.5 10 85 2 18 18 1.67 10 82 3 18 18 1.67 20 84 4 18 18 1.67 30 94 5 24 24 1.25 30 87 6a18 18 1.67 30 60 7b18 18 1.67 30 35 8c18 18 1.67 30 10 9d18 18 1.67 30 15 10e18 18 0.3 30 90 11f18 18 1.67 30 25 12g18 18 1.67 30 18 13h18 18 1.67 30 56 Reaction condition: 1a (0.25M in ACN), NBS (0.253M in ACN); 1 mL PFA reactor (id = 1mm, v = 1.3 mL); blue light (W); instead of ACN solvents (a) THF; (b) DCM; (c) DMF; (d) DMSO, (e) 1a in EA and NBS in ethyl acetate (EA): ACN (4:1) *due to partial solubility of NBS in EA; instead of blue light (f) red light (g) green light (h) white light; yields are based on LC-MS. General procedure for the assembly and integration of continuous photo-flow reactor:

[0005] 1 The first embodiment of an AI-based photo-flow reactor, illustrated in Figure 1, is designed for photochemical reactions. The automated optimization platform's success relied on an accurate predictive analytics model, utilizing the Mettler-Toledo ReactIR-15 with an Ag-halide Di-comp Flow Cell for real-time IR spectra recording at 15-second intervals. A 15-second scan time balanced reliability and rapid analysis. Mettler Toledo iC IR software (version 7.1) facilitated spectral data analysis, ensuring consistency with recorded background spectra. Initially, we compare the IR data of the reactant (Formula 3), NBS, pre- and post-light-exposed reaction mixtures, and the pure product (Formula 1) to find the signature peak for analysis. Using uniform absorption spectra of Formula 3 and 1, IR trend spectra streamlined model calibration, focusing on the 1100–1300 cm-1spectral region for its distinct C–BrwagIR peak at 1230 cm-1for Formula 1 (Fig. 2). The reactor features a photo-flow system with multiple microreactors. Pumps flow reactant (od = 1 / 16, od = 1 mm, volume 1-5mL) facilitating the flow pathway of reactants, blue light (0-60W) varied by a power supply (voltage 0-15, current 4-5 ampere) (figure 3), inline infrared (IR) for analysis and auto-collector. The integrated setup incorporates a power supply, light source, pump, and inline infrared (IR), all linked to a central computer system connected to a neural network. The automated platform is enhanced with Python code and Bayesian optimization (BO) code to enable self-optimized reactions. The Python program supported various functions, including mouse and keyboard control, with a key mouse control function being 'clicking.' In-line ReactIR15 utilized image processing in Spectra IR15 software, measuring FT- IR spectra and saving the data in 'csv' format. The Spyder function simulated a click to open the spectra analysis program, export the 'csv' file, and import it. This bridged the independent operations of React IR and Spyder, with In-line React IR managing spectroscopy measurements and Spyder processing data and providing feedback to the pumps. D graph to obtain the optimal parameter between flow rate, watt, and yield, 4a &4c of 0.25M & 0.5M concentration, respectively (Figure 4). 3D graph to obtain the optimal conditions between residence time, yield, and productivity residence time and watt mentioned in Figures 4b & 4d of 0.25M & 0.5M concentration, respectively. Also, we plot and find that a 96% yield of formula 1 was obtained in 1.0 min. and 60 watts (Figure 5) and isolated yield 94%. Integrated photo-flow synthesis, quenching, and extraction of formula 1: The represented compound of formula 1 is 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile (formula 1a), 1-(bromomethyl)-4-iodobenzene (1b), 1-bromo-4-(bromomethyl)benzene (1c), 1- (bromomethyl)-4-chlorobenzene (1d), 4-(bromomethyl) benzonitrile (1e), 1-(bromomethyl)-4- nitrobenzene (1f), 1-(bromomethyl)-3-iodobenzene (1g), 1-(bromomethyl)-3-iodo-5- methylbenzene (1h), 1-(bromomethyl)-3,5-dimethylbenzene (1i), 1-(bromomethyl)-2- iodobenzene (1j), 2-(bromomethyl)benzonitrile (1k), 1-(bromomethyl)-2-nitrobenzene (1l), 2- bromo-1-(bromomethyl)-3-methylbenzene (1m), 1-bromo-2-(bromomethyl)naphthalene (1n), 9- bromo-9H-fluorene (1o). In another embodiment of the present invention related, autonomously explored bromination conditions are seamlessly integrated with continuous flow tools to synthesize, extract, and purify synthesis of formula 1. In a preferred embodiment, the middle part membrane micro-separator assembles a specially designed laser-grooved micro-patterned PTFE sheet with a hydrophobic PTFE membrane, wherein the hydrophobic membrane has an average pore size of 0.25-0.45 mm. In embodiment, the present invention provides an integrated process for the photochemical reaction, quenching, and extraction for the synthesis formula 1 comprising the steps of: An introducing of a solution formula 3 in ACN and an NBS in EA: ACN (4:1) at T- mixer and passing through equal flow rate to maintain stoichiometric ratio in 5mL reactor under 60W blue light for 1 min residence time the completion of the reaction. Then water was introduced into the reaction mixture after light exposure through a T-mixer (T2) and gradually moved to the aqueous droplet phase and real-time extraction through a PTFE capillary (od = 3.18 mm, id= 2.0 mm, l = 2.0 m, v = 6 mL) for extraction (0.3-0.8 min). Next, the solution passed through a liquid-liquid separator (30 mL volume) developed and previously reported by our laboratory to facilitate extraction, Green Chemistry 24, 4794-4799 (2022) for the aqueous waste removal of the crude organic solution containing the brominated compound, a residence time of (1.2 – 4.2 min) and a pressure of 1 bar were determined to be sufficient the crude organic solution analysis using LC- MS (Table 2). After studying several reaction conditions, an integrated synthesis of formula 1 was obtained in 3.4 min residence time at ambient temperature with an isolated 94% yield. The further present invention, related, autonomously explored bromination conditions are applied for the various substituted toluenes to synthesize formula 1. Table 2. Optimization of byproduct removal from aqueous-organic extraction work-up step. H2O Flow rate Residence time (min) Removal Entry (mL / h) Extraction Separation (%) of byproduct 1 120 0.8 4.2 60 2 300 0.6 3 70 3 480 0.46 2.3 90 4 600 0.4 2 99 5 900 0.3 1.2 99 Reaction Condition: Formula 3a (0.25 M in EA), NBS [0.25 M in EA: ACN (4:1)]; extraction reactor (od = 3.18 mm, id = 2 mm, l= 2 m, v= 6 mL); separator volume 30 mL; byproduct removal from organic layer analysis by LC-MS and crude1H NMR. General procedure for the solar tracker continuous flow reactor for lab-scale photochemical reaction: In another embodiment of the present invention, related, lab scale solar tracker continuous platform for the photochemical bromination for the synthesis of formula 1. The lab scale solar tracker continuous platform (8 mL) has been disclosed in prior art Green Chemistry, 24, 4794-4799 (2022). In prior art, the extension of that reactor has been used for photo-flow bromination for the lab-scale synthesis of formula 1. A stock solution of formula 3 and NBS in ACN solvent was taken in a bottle and connected with a pump, as described in Figure 6. The flow rate of the formula 3 and NBS solutions was kept varied by the residence time passed through the solar panel tracker (PFA tubing, inner diameter (id) = 1mm, length = 10-20 m, volume = 8.0 mL and 16 mL) for the reaction to occur. A residence time of 0.32-2.66 min, sunlight or blue light, and ambient pressure of 0-2 bar were tested for the bromination of formula 3 to form the compound of formula 1 (Table 3). After studying several reaction conditions, finally isolated 92% yield of formula 1 for under solar tracker photo-flow bromination was obtained in 0.53 residence time at ambient temperature with 112 g / h (figure 6). Table 3 Optimization of lab-scale solar panel tracker continuous flow platform for synthesis of formula 1.

[0006] y Formula 3aNBS(min) (%)b1 90 90 2.66 90 2 120 120 2.5 91 3 150 150 1.6 93 4 240 240 1.0 92 5 300 300 0.8 93 a 6 600 600 0.8 93 a 7 750 750 0.63 94 a 8 840 840 0.57 95 a 9 900 900 0.53 97 (92)ca 10 1050 1050 0.45 85 b 11 60 60 4 86 12b120 120 4 78 Reaction condition: 0.5 M of formula 1 in ACN, 0.505 M of NBS in ACN, solar tracker reactor (PFA tubing, od = 1.58, id = 1mm, l = 10.2 m, v = 8 mL; (a) solar tracker panel reactor (PFA tubing, od = 1.58, id = 1mm, l = 20.4 m, v = 16 mL); (b) 0.5 M of formula 1 in DCE, 0.50 M of Br2 in DCE, solar tracker reactor (PFA tubing, od = 1.58, id = 1mm, l = 10.2 m, v = 8 mL; yields calculated on the crude LC-MS and1H NMR analysis; yield in parenthesis indicated isolated yield. General procedure for the assembly of the solar tracker continuous flow pilot-scale reactor for photochemical reaction. In another embodiment, the present invention designs and utilizes a solar tracker continuous flow pilot-scale reactor for a photochemical reaction to synthesize formula 1. The electromechanical device follows the sun's trajectory and solution flow rate depending on the light intensity. The present invention provides the development of a pilot-scale solar tracker photo-flow reactor for photochemical bromination, providing a synthesis of Formula 1 with excellent space-time yield. The solar tracker photo-flow reactor (Figure 7) devised for photochemical bromination comprised of: A syringe pump system (2) comprising a plurality of syringes (3) for operable connected with a tube carrying the mixture of reactants connect to the solenoid valve (4) and solenoid valve is connected to a light-dependent resistor (LDR) microcontroller system (5) to controlled the direction of flow in T-mixer or return in the stock solution depends upon light intensity. Suppose cloudy weather is abstracting the light intensity below 50000lux, then the solution returns to stock solution and if intensity of light is above 50000 lux, then the solution introduced at T-mixer (6) and further infusing the solution to the mixing zone (7) (od = 1 / 8, id = 2.54 mm, v = 10 mL) for more mixing of reagents using 1 / 8 to 1 / 4 extender (8) passing through a solar tracker for interacting the reaction mixture for sunlight exposure (figure 7). A solar reactor comprising a variety of PFA tubes reactors (9) such as (od = 1 / 8, id = 1mm, l = 10.2 or 20.3 m, v = 8 mL or 16 mL) or (od = 1\4, id = 4 mm, l = 83 m, v = 1 L) mounted on the SS meshed sheet (10). The tube reactor carrying the reactants at one end performed a reaction under solar irradiation and collected the product (14) at the other end; A solar panel switch (11), a solar panel stepper motor (12) to track the sun's trajectory, and a parabolic antenna (13) are all incorporated to control the motor speed and solar panel reactor movement independently. At the same time, an SS mesh sheet was placed over the parabolic antenna with PFA tubing to perform a sunlight-mediated photochemical reaction. A stock solution containing formula 3a and brominating reagents (NBS / Br2) in solvents with various molar ratios was taken in a stock solution container connected to a syringe pump. Both solution phase was passed through an above-designed large-scale solar reactor containing perfluoroalkyl (PFA) tubing reactor (od = 1\4, id = 4 mm, l = 83 m, v = 1 L). The solar panel reactor was exposed to sunlight to proceed with the reaction. The product mixture was collected into a flask at the end of the photo-flow reactor. As mentioned in Table-3, various reaction parameters (retention time) were regulated to optimize reaction performance. Finally, after studying several reaction conditions, a 94 % yield of Formula 1 (Table 1, Entry 2) was obtained in 5 min of residence time under the solar light and 1 bar pressure. Table 4 Optimization of lab-scale solar panel tracker continuous flow platform for synthesis of formula 1. Flow rate (mL / h) Res. time Yield Entry Formula 2 Formula 3 (Seconds) (%)b1 3000 3000 10 94 2 6000 6000 5 93 Reaction Condition: 0.5 M of formula 1 in ACN, 0.505 M of NBS in ACN, (od = 1 / 4, id = 4mm, l = 83 m, v = 1.0 L); yields calculated on the1H NMR analysis. General procedure for Nucleophilic substitution reaction for C-N coupling A stock solution of Formula 1a in EA (0.1M) and Formula 4a in DMF (0.105) is in bottles and connected to the pump. Both solutions were introduced into a T-mixer with varied flow rates to maintain the stoichiometric ratio by the residence time passed through a varied volume of SS- packed bed reactor (7ml or 100mL) for the reaction to occur with varied temperatures. A pack bed reactor tested Various bases such as K2CO3, Na2CO3, KOH, and Amberlyst-15 hydroxide for nucleophilic substitution. A residence time of 2.27-6.67 min., at temperature 25-80oC 0-2 bar, was enough for the nucleophilic substitution of Formula 1a with Formula 4a to form the compound of Formula 2 (Table 5). Next, the product was collected in a cold-water reservoir, extracted with EA, and further purified by following procedures known in the prior art. After studying several reaction conditions, an isolated 89% yield of formula 2a was finally obtained in 0.3.4 residence time at 60oC temperature (Table 5, entry 13). Table 5 Optimization table of the nucleophilic substitution for the synthesis of 3a. 1a 4a (min) (%) 1 12 12 25 5.0 40 2 15 15 50 5.0 70 3 12 12 60 5.0 80 4 12 12 80 5.0 80 5 9 9 60 6.67 96 5a9 9 25 6.67 30 6b9 9 60 6.67 30 7c9 9 60 6.67 53 8d9 9 60 6.67 92 9e9 9 60 6.67 65 10f9 9 60 6.67 50 11g180 180 60 5.67 95 12g240 240 60 4.25 96 13g300 300 60 3.4 95 (89) 14g450 450 60 2.27 70 Reaction condition: 0.1 M of formula 1a in EA and 0.105 M of formula 4a in DMF, 7.0 mL SS packed bed reactor (id = 6 mm, l = 150 mm, free vol.2.0 mL), K2CO3; (a) KOH, (b) Na2CO3; (c) Amberlyst 15 hydroxide; (d) toluene; (e) acetone; (f) ACN; (g) 100 mL SS packed bed reactor (id = 22 mm, l = 270 mm, v = 100 mL, free vol. K2CO3 filling 34 mL),); yield based on the crude LC- MS analysis; yield in parenthesis indicated isolated yield. General procedure for Integrated platform for the Nucleophilic substitution reaction for C- N coupling. An introduction of a solution formula 3a in ACN and an NBS in EA: ACN (4:1) at T- mixer (T1) and passing through 150mL / h rate to maintain the stoichiometric ratio in 5mL reactor under 60W blue light for 1 min residence time the completion of the reaction. Then water was introduced at 600mL / h into the reaction mixture after light exposure through a T-mixer (T2) and gradually moved to the aqueous droplet phase and real-time extraction through a PTFE capillary (od = 3.18 mm, id= 2.0 mm, l = 2.0 m, v = 6 mL) for extraction (0.4 min). Next, the solution passed through a liquid-liquid separator (30 mL volume) developed and previously reported by our laboratory to facilitate extraction, Green Chemistry 24, 4794-4799 (2022) for the aqueous waste removal of the crude organic solution containing the brominated compound, a residence time of (2.0 min) and a pressure of 1 bar were determined to be sufficient the crude organic solution analysis using LC- MS (Table 1). Using two separate pumps, the outflowing crude mixture from separator formula 1a in EA and stock solution formula 4a in DMF (0.136 M) were introduced into a T-mixer (T3). The combined mixture passed through a 100 mL SS-packed bed (id = 22 mm, l = 270 mm, v = 100 mL, free vol. K2CO3 filling 34 mL) reactor for the nucleophilic substitution reaction. The flow rates of formula 1a & formula 4a have varied to maintain the stoichiometry (Table 5). After studying several reaction conditions, an isolated 82% yield of formula 2a was finally obtained in 3.8 residence time at 80oC temperature (Table 6, entry 3). Table 6. Optimization of an integrated platform for the Wohl Ziglar Bromination and Nucleophilic Substitution.

[0007] Flow rate (mL / h)Res. time4a Entry 1a 4a(min) Yield (%) 240 240 4.25 84 2 300 300 3.4 77 3 270 270 3.8 82 4 360 360 2.8 71 Reaction Condition: Formula 1 from separator (approximately 0.13 M in EA); Formula 4a (0.136M) in DMF; 100 mL SS-packed bed (id = 22 mm, l = 270 mm, v = 100 mL, free vol. K2CO3 filling 34 mL) reactor; yield based on isolated yield. Material and method used in experiments Most of the reagents and chemicals are bought from Spectrochem, AVRA, and Sigma-Aldrich, which were used as such without any further purification. Common organic chemicals and salts were purchased from AVRA Chemicals, India. Deionized water (18.2 mS conductivity) was used in all experiments. All work-up and purification procedures were carried out with reagent-grade solvents. Analytical thin-layer chromatography (TLC) was performed using analytical chromatography silica gel 60 F254 pre-coated plates (0.25 mm). The developed chromatogram was analyzed by UV lamp (254 nm). PTFE (id = 1-4 mm) tubing, T-junction, X-junction, and back-pressure controller (BPR) were procured from Upchurch IDEX HEALTH & SCIENCE. The pump was purchased from KNAUER. The SS318 capillary was bought from the spectrum market in Mumbai, India. The heating reactor was purchased from Thales Nano Nanotechnology, Inc. Measurement Method High-resolution mass spectra (HRMS) were obtained from a JMS-T100TD instrument (DART) and Thermo Fisher Scientific Exactive (APCI). Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 600, 500, 400, or 300 MHz in CDCl3 or DMSO-d6 solvent. Chemical shifts for1H NMR are expressed in parts per million (ppm) relative to tetramethylsilane (δ 0.00 ppm). Chemical shifts for13C NMR are expressed in ppm relative to CDCl3 (δ 77.0 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, quin = quintet, sext = sextet, m = multiplet), coupling constant (Hz), and integration. GC / MS analysis was conducted on Shimadzu technology GCMS-QP2010 instrument equipped with an HP-5 column (30 m × 0.25 mm, Hewlett-Packard) and inbuilt MS 5975C VL MSD system with triple axis detector. ATR analysis was conducted on the Portable FTIR spectrometer Bruker ALPHA. EXAMPLES The following examples, which include preferred embodiments, will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purpose of illustrative discussion of preferred embodiments of the invention and therefore should not be construed to limit the scope of the present invention. In examples, the quantities and percentages are given by weight unless stated otherwise. Example 1 to 15: General procedure for the synthesis of formula 1 and thereof using formula 3 using an artificial light flow reactor. A solution of formula 3 in solvent and formula brominating agents’ solvent. Both solutions are connected through the pump. Both reactants were introduced through a T-mixer (T1) in a varied flow rate (0-200 mL / h) to maintain the stoichiometry and then passed through a PFA tubing (1-5 mL) to a homemade photo-flow reactor under the varied intensity of blue light for the irradiation of light. The out-flowing product mixture solution was further connected with the in-line IR to the product analysis. After the reaction, remove the byproduct by introducing water (0-600 mL / h) to form organic-aqueous droplets. Complete extraction between organic-aqueous segments was accomplished by flowing through a 6 mL PTFE reactor. The separation was achieved by passing through the homemade-designed homemade liquid-liquid separator. The collected crude organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under a vacuum. Example 1: 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile (1a) Two stock solutions, Formula 3a (0.25 M in EA, 24.12 g in 500 mL) and NBS (0.253 M in EA: ACN, 4:1, 23.36 g in 500 mL), were 30 combined using a T-mixer at a flow rate of 150 mL / h each, passing through a PFA 5 mL to a homemade photo-flow reactor exposed to 60W blue light. The reactor's out-flowing mixture was connected to a T-junction, introducing water (600 mL / h) to remove byproducts, forming organic-aqueous droplets. Complete extraction was achieved within 0.4 min residence time through a 6 mL PTFE reactor. Subsequently, complete separation occurred in a homemade liquid-liquid separator within 2.0 min residence time. The initial 10 min of the reaction mixture was discarded, followed by collection for 2.5 h (675 mL). The collected mixture was dried over anhydrous Na2SO4, filtered, and concentrated under a vacuum. The compound was purified using silica gel column chromatography with a hexane / EA gradient (100:10) to get 94% (23.97 g) Melting point: 117oC;1H NMR (400 MHz, CDCl3): δ 7.76 (dd, J = 7.8, 1.0 Hz, 1H), 7.64 (td, J = 7.7, 1.3 Hz, 1H), 7.56 – 7.48 (m, 5H), 7.45 (td, J = 7.6, 1.2 Hz, 1H), 4.54 (s, 2H);13C NMR (101 MHz, CDCl3): δ 144.70, 138.35, 138.20, 133.84, 132.96, 130.05, 129.46, 129.23, 127.86, 118.63, 111.22, 32.89; IR ( max): 3025, 2222, 1595, 1475, 1440,1408, 1218, 881, 829, 756, 673 cm-1; HRMS: [M + Na] Calcd for C14H10NBrNa 293.9889, found 293.9880. Example 2: 1-(bromomethyl)-4-iodobenzene (1b) 15 The compound of formula 1b was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange with 4-iodo toluene. The crude material was purified by silica gel column chromatography in hexane to provide a white solid (666 mg) with a 90% yield. Melting Point: 74oC;1H NMR (400 MHz, CDCl3): δ 7.68 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.3 Hz, 2H), 4.42 (s, 2H); 13C NMR (101 MHz, CDCl3): δ 138.05, 137.51, 130.95, 94.29, 32.63; IR ( max):3019, 2960, 2924, 1900, 1781, 1651, 1581, 1473, 1394, 1271, 1216, 1087, 1055, 1000, 949, 909, 812, 736 cm-1. Example 3: 1-bromo-4-(bromomethyl) benzene (1c) The compound of formula 1c was synthesized according to the general 25 procedure described in example 1 involving corresponding reactant exchange with 4-bromo toluene. The crude material was purified by silica gel column chromatography in hexane to provide a white solid (576 mg) with a 93% yield. The spectra data compared with those reported in the literature.4, 5Melting Point: 58oC;1H NMR (400 MHz, CDCl3): δ 7.46 (d, J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 4.43 (s, 2H);13C NMR (126 MHz, CDCl3): δ 136.91, 132.10, 131.96, 130.79, 128.27, 122.59, 32.52; IR ( max): 3019,2961, 2920, 1903, 1589, 1485, 1435, 1403, 1221, 1012, 826, 755 cm-1. Example 4: 1-(bromomethyl)-4-chlorobenzene (1d) The compound of formula 1d was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange with 4-chloro toluene. The crude material was purified by column chromatography in hexane to provide a white solid (466 mg) with a 91% Yield. Melting Point: 46oC;1H NMR (400 MHz, CDCl3): δ 7.32 (s, 4H), 4.45 (s, 2H);13C NMR (151 MHz,CDCl3): δ 136.41, 134.41, 130.50, 129.12, 32.53; IR ( max): 3060, 1906, 1713, 1595, 1488, 1282,122, 1087, 1014, 874, 829 cm-1. Example 5: 1-(bromomethyl)-4-benzonitrile (1e) 10 The compound of formula 1e was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange with 4-cyano toluene. The crude material was purified by column chromatography in hexane to provide a white solid (465 mg) with a 95% yield. Melting Point: 115oC;1H NMR (400 MHz, CDCl3): δ 7.64 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.3 Hz, 2H), 4.47 (s, 2H);13C NMR (101 MHz, CDCl3): δ 142.93, 132.68, 129.82, 118.47, 112.30, 31.60; IR( max): 2915, 2223, 1604, 1502, 1410, 1286, 1219, 1098, 841, 816, 764 cm-1.Example 6: 1-(bromomethyl)-4-nitrobenzene (1f) The compound of formula 1f was synthesized according to the general procedure described in example 1 involving corresponding reactant 20 exchange with 4-nitro toluene. The crude material was purified by column chromatography in hexane to provide a white solid with a 90% (486 mg) yield. Melting Point: 87oC;1H NMR (400 MHz, CDCl3): δ 8.21 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 8.7 Hz, 2H), 4.52 (s,2H); 13C NMR (126 MHz, CDCl3): δ 147.83, 144.90, 130.06, 124.19, 31.05; IR ( max): 2922,2856, 1607, 1536, 1458, 1381, 1348, 1226, 1099, 858, 801 cm-1. Example 7: 1-(bromomethyl)-3-iodobenzene (1g) The compound of formula 1g was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange with 3-iodo toluene. The crude material was purified by column chromatography in hexane to provide a white solid (629 mg) with an 85% yield. Melting Point: 46oC;1H NMR (400 MHz, CDCl3): δ 7.74 (t, J = 1.6 Hz, 1H), 7.63 (dd, J = 7.9, 1.1 Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.07 (t, J = 7.8 Hz, 1H), 4.39 (s, 2H);13C NMR (126 MHz,CDCl3): δ 139.96, 137.92, 137.47, 130.48, 128.32, 94.32, 31.96; IR ( max): 3012, 2921, 2857,1737, 1462, 1377, 1218, 1079, 973, 835, 764, 689 cm-1. Example 8: 1-(bromomethyl)-3-iodo-5-methylbenzene (1h) 5 The compound of formula 1h was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange with 1-iodo-3,5-dimethylbenzene. The crude material was purified by column chromatography in hexane to provide a white solid (635 mg) with 82% yield.1H NMR (500 MHz, CDCl3): δ 7.53 (s, 1H), 7.46 (s, 1H), 7.15 (s, 1H), 4.35 (s, 2H), 2.29 (s, 3H);13C NMR (101 MHz, CDCl3): δ 140.70, 139.64, 138.14, 134.98, 129.24, 94.29,32.16, 20.95; IR ( max): 3021, 2955, 2913, 2855, 1595, 1563, 1438, 1374, 1255, 1208, 1121,1039, 994, 851, 793 cm-1. Example 9: 1-(bromomethyl)-3,5-dimethylbenzene (1i) The compound of formula 1i was synthesized according to the general 15 procedure described in example 1 involving corresponding reactant exchange with 1,3,5-trimethylbenzene. The crude material was purified by silica gel column chromatography in hexane to provide a white solid (408 mg) with a 65% yield. The spectra data compared with those reported in the literature.7 1H NMR (500 MHz, CDCl3): δ 7.03 (s, 2H), 6.95 (s, 1H), 4.45 (s, 2H), 2.32 (s, 6H);13C NMR (126 MHz, CDCl3): δ138.46, 137.65, 130.23, 126.88, 33.96, 21.24; IR ( max): 3017, 2959, 2917, 2863, 1606, 1525,1463, 1379, 1303, 1212, 1161, 1118, 1035, 944, 849, 759 cm-1. Example 10: 1-(bromomethyl)-2-iodobenzene (1j) The compound of formula 1j was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange 25 with 2-iodo toluene. The crude material was purified by column chromatography in hexane to provide a white solid (600 mg) with an 81% yield. Melting Point: 53oC;1H NMR (400 MHz, CDCl3): δ 7.86 (dd, J = 7.9, 1.1 Hz, 1H), 7.48 (dd, J = 7.7, 1.6 Hz, 1H), 7.34 (td, J = 7.5, 1.2 Hz, 1H), 6.98 (td, J = 7.7, 1.7 Hz, 1H), 4.60 (s, 2H);13C NMR (101MHz, CDCl3): δ 140.31, 140.20, 130.61, 130.20, 129.00, 100.18, 38.90; IR ( max): 3057, 2922,2855, 1573, 1465, 1438, 1277, 1014, 813, 756 cm-1. Example 11: 1-(bromomethyl)-2-benzonitrile (1k) The compound of formula 1k was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange with 2-cyano toluene. The crude material was purified by column chromatography in hexane: EA (98:2) to provide a white solid (523 mg) with an 85% yield. Melting Point: 74oC;1H NMR (500 MHz, CDCl3): δ 7.66 (dd, J = 7.7, 1.0 Hz, 1H), 7.58 (dtd, J = 9.1, 7.8, 1.3 Hz, 2H), 7.42 (td, J = 7.5, 1.5 Hz, 1H), 4.64 (s, 2H);13C NMR (101 MHz, CDCl3): δ141.24, 133.39, 133.31, 130.59, 129.07, 116.87, 112.55, 29.45; IR ( max): 3026, 2229, 1721,1601, 1488, 1449, 1295, 1222, 830, 764 cm-1. Example 12: 1-(bromomethyl)-2-nitrobenzene (1l) 10 The compound of formula 1l was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange with 2-nitro toluene. The crude material was purified by column chromatography in hexane: EA (98:2) to provide a pale-yellow liquid (378 mg) with a 70% yield. 1H NMR (400 MHz, CDCl3): δ 8.02 (dd, J = 8.2, 1.2 Hz, 1H), 7.65 – 7.55 (m, 2H), 7.52 – 7.43 (m, 1H), 4.82 (s, 2H);13C NMR (151 MHz, CDCl3): δ 148.02, 133.83, 132.85, 132.62, 129.73, 125.55, 29.01; IR ( max): 2924, 2859, 1574, 1529, 1440, 1349, 1308, 1225, 860, 791, 753 cm-1.Example 13: 2-bromo-1-(bromomethyl)-3-methylbenzene (1m) The compound of formula 1m was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange 20 with 2-bromo-1,3-dimethylbenzene. The crude material was purified by silica gel column chromatography in hexane to provide a white solid (443 mg) with a 72% yield.11 1H NMR (400 MHz, CDCl3): δ 7.26 (t, J = 4.5 Hz, 1H), 7.21 – 7.12 (m, 2H), 4.62 (d, J = 1.0 Hz, 2H), 2.41 (s, 3H);13C NMR (101 MHz, CDCl3): δ 139.49, 137.39, 131.06, 128.76, 127.34, 127.13, 34.75, 23.88; IR ( max): 3054, 2973, 2853, 1578, 1447, 1382, 1262, 1212, 1166,1026, 933, 863, 773, 718 cm-1. Example 14: 1-bromo-2-(bromomethyl) naphthalene (1n) The compound of formula 1n was synthesized according to the general procedure described in example 1 involving the corresponding reactant exchange 1-bromo-2-methylnaphthalene. The crude material was purified by silica gel column chromatography in hexane to provide a white solid (568 13Melting Point: 101oC;1H NMR (400 MHz, CDCl3): δ 8.37 – 8.28 (m, 1H), 7.84 – 7.74 (m, 2H), 7.60 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.53 (ddd, J = 13.7, 7.6, 4.1 Hz, 2H), 4.85 (s, 2H);13C NMR (101 MHz, CDCl3): δ 135.05, 134.26, 132.63, 128.44, 128.28, 127.98, 127.85, 127.75, 127.33, 125.09, 34.91; IR ( max): 3044, 1597, 1556, 1499, 1329, 1260,1213, 1108, 1028, 979, 861, 812, 757 cm-1. Example 15: 9-bromofluorene (1o) The compound of formula 1o was synthesized according to the general procedure described in example 1 involving corresponding reactant exchange with fluorene. The crude material was purified by column chromatography in hexane to provide a white solid (539 mg) with an 88% yield. Melting Point: 105oC;1H NMR (400 MHz, CDCl3): δ 7.66 (t, J = 8.1 Hz, 4H), 7.39 (td, J = 7.4, 0.9 Hz, 2H), 7.34 (td, J = 7.4, 1.2 Hz, 2H), 6.00 (s, 1H);13C NMR (126 MHz, CDCl3): δ144.15, 139.78, 129.20, 128.07, 126.35, 120.25, 46.03; IR ( max): 3030, 1607, 1447, 1217, 1186,1133, 940, 854 cm-1. Example 16 to 17: The synthesis procedure of Formula 1a uses a lab-scale solar tracker flow reactor. 1. A stock solution of formula 3a and brominating agent in ACN solvent was taken in a bottle and connected with a pump, as described in Figure 6. 2. The flow rate of the formula 3a and brominating agent solutions were kept varied by the residence time passed through the solar panel tracker (inner diameter (id) = 1mm-4mm, length = 10-83 m, volume = 8.0 mL to 1.0 L) for the reaction to occur. 3. Various light sources and brominating reagents (NBS or Br2) were tested for the bromination reaction. 4. A residence time of 0.32-20 min and sun-light at an ambient pressure of 0-2 bar was enough for the bromination of formula 3a to form the compound of formula 1a (Table 4&5). 5. Next, the reaction mixture solvent was removed under the vacuum, and the product was further purified by following procedures known in the prior art. Example 16: Procedure of the lab-scale continuous flow photochemical bromination of the solar tracker platform to synthesize formula 1. A solution of Formula 3a in ACN [ 0.5 M (724 g in 7.5L)], and a solution of Formula NBS in ACN [ 0.5 M (674 g in 7.5L)]. These stock solutions were introduced into a T-mixer at a flow rate of 900 mL / h for each solution and then passed through the (od =1.58, id = 1mm, l = 20.4 mm, vol. = 16 mL) solar tracker reactor for light irradiation and residence time 32 sec was enough for the complete reaction. The first two-min reaction mixture was discarded, then collected for 8h, and ACN was distilled from the reaction mixture up to 80%. Then, add water, get precipitated, and wash two times with hot water to remove the byproduct. Then, the residue dissolved in EA, dried over anhydrous Na2SO4, filtered, and concentrated under a vacuum. The compound was purified using silica gel column chromatography with a hexane / EA gradient (100:10) to get 92% isolated yield and 896 g for 8h productivity. Example 17: Procedure of the pilot-scale continuous flow photochemical bromination of the solar tracker platform to synthesize Formula 1. A solution of Formula 3a in ACN [ 0.5 M (1.46 kg in 10 L)] and a solution of NBS in ACN [ 0.505 M (0.898 kg in 10 L)]. These stock solutions were introduced into a T-mixer at a flow rate of 6 L / h for each solution and then passed through the (od =1 / 4, id = 4 mm, l = 83 m, vol. = 1 L) solar tracker reactor for light irradiation and residence time 5.0 min was enough for the complete reaction. The first 10-minute reaction mixture was discarded and then collected for 1h, and ACN was distilled from the reaction mixture up to 80%. Then, add water, get precipitated, and wash more times with hot water to remove the byproduct and dry under a vacuum. The compound was purified using silica gel column chromatography with a hexane / EA gradient (100:10) to get 94% yield and 750 g / h productivity. Example 18 to 33 General procedures for the continuous flow nucleophilic substitution for the synthesis of formula 2. 1. A stock solution formula 1a in EA (0.1-0.13 M) and Formula 4 in DMF (0.105-0.14 M) in Bottles and connected with the pump. 2. both solutions were introduced into a T-mixer with varied flow rates to maintain the stoichiometric ratio by the residence time passed through a varied volume of SS-packed bed reactor (7ml or 100mL) for the reaction to occur with varied temperatures. 3. A pack bed reactor tested Various bases such as K2CO3, Na2CO3, KOH, and Amberlyst-15 hydroxide for nucleophilic substitution. 4. A residence time of 2.27-6.67 min., at temperature 25-80oC 0-2 bar, was enough for the nucleophilic substitution of formula 1a with formula 4 to form the compound of Formula 2 (Table 5). 5. Next, the product was collected in a cold-water reservoir, extracted with EA, and further purified by following procedures known in the prior art. Example 18: 4'-((2-Butyl-4-chloro-5-formyl-1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2- carbonitrile (Losartan intermediate) (2a) 5 A stock solution formula 1 (0.1 M, 16.32 g in 600 mL EA) and Formula 4a (0.105 M, 11.72 in 600 mL DMF) these two solutions were introduced into a T-mixer with each flow rate of 300 L / h to maintain the stoichiometric ratio and then passed through a 100 mL SS-packed bed reactor (id = 22 mm, l = 270 mm, v = 100 mL, free vol. K2CO3filling 34 mL) at 60 °C temperature. A 3.4 min residence time was a complete reaction. The first 10 min reaction mixture was discarded and then collected for 1.5 h (900 mL). The product was collected in a cold-water reservoir and extracted with EA. The organic layer was washed twice with water, dried over anhydrous Na2SO4, filtered, and concentrated under a vacuum. The crude mixture was purified by silica gel column chromatography in hexane: EA (70:30) to provide a pale-yellow solid with an 89 % (15.1 g) isolated yield. Melting Point: 104oC;1H NMR (400 MHz, CDCl3): δ 9.77 (s, 1H), 7.76 (dd, J = 7.7, 0.9 Hz, 1H), 7.64 (td, J = 7.7, 1.4 Hz, 1H), 7.58 – 7.51 (m, 2H), 7.50 – 7.39 (m, 2H), 7.18 (d, J = 8.3 Hz, 2H), 5.62 (s, 2H), 2.71 – 2.64 (m, 2H), 1.78 – 1.66 (m, 2H), 1.37 (dd, J = 15.0, 7.5 Hz, 2H), 0.90 (t, J = 7.3 Hz, 3H);13C NMR (101 MHz, CDCl3): δ 177.98, 154.68, 144.58, 143.21, 137.92, 136.19, 133.82, 132.95, 130.02, 129.38,127.84, 126.78, 124.33, 118.56, 111.19, 47.97, 29.28, 26.56, 22.41, 13.71; IR ( max): 2956, 2865,2226, 1664, 1516, 1471, 1423, 1376, 1273, 763, cm-1; HRMS: (M+H) calcd for C22H21N3OCl 378.1373, found 378.1360. Example 20: 4'-((2-Butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl) methyl)-[1,1'- biphenyl]-2-carbonitrile (Losartan intermediate) (2b) 25 The compound of formula 2b was synthesized according to the general procedure described in example 18 involving corresponding reactant exchange with (2-butyl-4-chloro-1H- imidazol-5-yl) methanol. The crude material was purified by column chromatography in hexane: EA (30:70) to provide a white liquid with a 54% yield. Melting Point: 159 °C;1H NMR (400 MHz, DMSO): δ 7.94 (dd, J = 7.7, 1.0 Hz, 1H), 7.78 (td, J = 7.7, 1.3 Hz, 1H), 7.64 – 7.53 (m, 4H), 7.25 (d, J = 8.3 Hz, 2H), 5.36 (s, 2H), 5.30 (t, J = 4.9 Hz, 1H), 4.39 (d, J = 4.5 Hz, 2H), 2.55 – 2.50 (m, 2H), 1.47 (d, J = 7.5 Hz, 2H), 1.23 (q, J = 7.4 Hz, 2H), 0.78 (t, J = 7.3 Hz, 3H);13C NMR (126 MHz, CDCl3): δ 148.65, 144.63, 137.79, 136.80, 133.82, 132.96, 130.00, 129.41, 127.83, 127.26, 126.29, 125.00, 118.57,111.19, 53.06, 47.22, 29.71, 26.75, 22.41, 13.74; IR ( max): 3223, 2956, 2866, 2226, 1574, 1454, 1417, 1353, 1252, 1073, 1011, 827, 755 cm-1; HRMS: (M+H) calcd for C22H23N3OCl 380.1530, found 380.1522. Example 21: Ethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-4-(2-hydroxypropan-2-yl)-2- propyl-1H-imidazole-5-carboxylate (Olmesartan intermediate) (2c) The compound of formula 2c was synthesized according to 10 the general procedure described in example 18 involving corresponding reactant exchange with ethyl 4-(2- hydroxypropan-2-yl)-2-propyl imidazole-5-carboxylate. The crude material was purified by column chromatography in hexane: EA (30:70) to provide a white solid with a 70% yield. Melting Point: 94 °C;1H NMR (400 MHz, CDCl3): δ 7.77 (dd, J = 7.7, 0.9 Hz, 1H), 7.65 (td, J = 7.7, 1.4 Hz, 1H), 7.56 – 7.42 (m, 4H), 7.05 (d, J = 8.3 Hz, 2H), 5.83 (s, 1H), 5.52 (s, 2H), 4.23 (q, J = 7.1 Hz, 2H), 2.81 – 2.53 (m, 2H), 1.75 – 1.72 (m, 2H), 1.65 (s, 6H), 1.16 (t, J = 7.1 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H);13C NMR (126 MHz, CDCl3): δ 161.62, 159.03, 151.49, 144.78, 137.80, 137.38, 133.81, 132.92, 129.99, 129.27, 127.76, 125.73, 118.59, 117.02, 111.27, 70.41, 61.34, 48.88, 29.38, 21.42, 13.92; IR ( max): 3388, 2974, 2227, 1670, 1529, 1462, 1389, 1289, 1215, 1166, 1053, 747 cm-1; HRMS:[M + H] calcd for C26H30N3O3432.2287, found 432.2299. Example 22: Diethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2-propyl-1H-imidazole-4,5- dicarboxylate (Olmesartan intermediate) (2d) The compound of formula 2d was synthesized according to the to – 7.73 (m, 1H), 7.64 (td, J = 7.8, 1.3 Hz, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.50 – 7.42 (m, 2H), 7.13 (d, J = 8.3 Hz, 2H), 5.48 (s, 2H), 4.40 (q, J = 7.1 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 2.73 – 2.64 (m, 2H), 1.75 (dq, J = 15.0, 7.4 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H);13C NMR (126 MHz, CDCl3): δ 163.11, 160.49, 151.96, 144.63, 137.84, 136.48, 136.34, 133.83, 132.92, 130.00, 129.34, 127.82, 126.54, 124.88, 118.53, 111.27, 61.65, 61.34, 48.02, 29.16, 21.39, 14.33, 13.92; IR ( max): 2971, 2226, 1716, 1455, 1287, 1203, 1110, 1022, 764, 629 cm-1; HRMS: [M + H] calcd for C26H28N3O4446.2080 found 446.2092. Example 23: 4'-((Imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2e) The compound of formula 2e was synthesized according to the general procedure described in example 18 involving corresponding reactant exchange with imidazole. The crude material was purified 10 by silica gel column chromatography in hexane: EA (50:50) to provide a white solid with an 83% yield.; Melting Point: 202oC;1H NMR (400 MHz, CDCl3): δ 7.77 (m, 1H), 7.65 (m, 1H), 7.60 (s, 1H), 7.55 (d, J = 8.2 Hz, 2H), 7.51 – 7.44 (m, 2H), 7.32 – 7.22 (m, 2H), 7.13 (s, 1H), 6.96 (s, 1H), 5.20 (s, 2H);13C NMR (101 MHz, CDCl3): δ 144.66, 138.17, 137.55, 136.86, 133.80, 132.96, 130.00, 129.42, 127.88, 127.50, 119.42, 118.59, 111.28, 50.43; IR ( max): 3063, 2964, 2225, 1654, 1471, 1413, 1362, 1275, 1117, 1024, 928, 825, 766,704, cm-1; HRMS: [M + H]+ calcd for C17H14N3260.1188, found 260.1187. Example24: 4'-((2-Methyl imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2f) The compound of formula 2f was synthesized according to the general – 7.43 (m, 2H), 7.17 (d, J = 8.5 Hz, 2H), Hz, 1H), 6.90 (d, J = 1.4 Hz, 1H), 5.13 (s, 2H), 2.38 (s, 3H);13C NMR (126 MHz, CDCl3): δ 145.02, 144.71, 137.88, 137.05, 133.81, 132.94, 130.00, 129.40, 127.83, 127.59, 126.91, 119.99, 118.60, 77.31, 77.05, 76.80, 49.40, 13.17; IR ( max): 2924, 2855, 2224, 1597, 1473, 1420, 1355, 1278, 1129, 1077, 990, 761 cm-1; HRMS:[M + H]+ calcd for C18H16N3274.1344, found 274.1339. Example 25: 4'-((2-Phenyl imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2g) 30 The compound of formula 2g was synthesized according to the to NMR (500 MHz, CDCl3): δ 7.77 – 7.74 (m, 1H), 7.64 (td, J = 7.7, 1.2 Hz, 1H), 7.59 – 7.52 (m, 4H), 7.49 (d, J = 7.7 Hz, 1H), 7.47 – 7.39 (m, 4H), 7.23 – 7.18 (m, 3H), 7.02 (d, J = 1.2 Hz, 1H), 5.29 (s, 2H);13C NMR (126 MHz, CDCl3): δ 148.36, 144.67, 137.83, 137.64, 133.82, 132.97, 130.49, 130.03, 129.41, 129.20, 128.96, 128.83, 128.69, 127.85, 126.92, 121.35, 118.64, 111.22, 50.07; IR ( max): 3060, 2924, 28961, 2226, 1610, 1491, 1368, 1273, 1197, 1118, 1009, 825, cm-1 HRMS: [M + H] calcd for C23H18N3336.1501, found 336.1494. Example 26: Methyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2-ethoxy benzimidazole-7- carboxylate (candesartan intermediate) (2h) The compound of formula 2h was synthesized according to the by to , 1.2 Hz, 2H), 7.45 – 7.38 (m, 4H), 7.18 (t, J = 7.9 Hz, 1H), 7.10 (d, J = 8.4 Hz, 2H), 5.69 (s, 2H), 4.67 (q, J = 7.1 Hz, 2H), 3.75 (s, 3H),1.49 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCl3): δ 166.86, 158.75, 144.98, 141.95, 138.08, 137.05, 133.78, 132.82, 131.51, 129.99, 128.90, 127.59, 126.86, 123.64, 121.99, 120.96, 118.64, 115.85, 111.21, 66.82, 52.33, 47.05, 14.69; IR ( max):3020, 2981, 2225, 1708, 1615, 1548, 1478, 1427, 1351, 1279, 1249, 1215, 1129, 1038, 741, 666 cm-1HRMS: [M + H] calcd for C25H22N3O3412.1661, found 412.1669. Example 27: Ethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2-ethoxy benzimidazole-7- carboxylate (candesartan intermediate) (2i) The compound of formula 2i was synthesized according to the general procedure described in example 18 involving corresponding reactant exchange with ethyl 2-ethoxy 30 benzimidazole-7-carboxylate. The crude material was purified by column chromatography in hexane: EA (70:30) to provide a white solid with a 75% isolated yield. Melting Point: 135oC;1H NMR (400 MHz, CDCl3): δ 7.74 (dd, J = 7.9, 1.1 Hz, 2H), 7.63 – 7.55 (m, 2H), 7.46 – 7.39 (m, 4H), 7.18 (t, J = 7.9 Hz, 1H), 7.10 (d, J = 8.4 Hz, 2H), 5.71 (s, 2H), 4.67 (q, J = 7.1 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 1.49 (t, J = 7.1 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H);13C NMR (101 MHz, CDCl3): δ 166.42, 158.71, 144.97, 141.93, 138.17, 137.01, 133.80, 132.82, 131.50, 129.97, 128.91, 127.57, 126.84, 123.62, 121.88, 120.92, 118.63, 116.25, 111.19, 66.79, 61.26, 47.00, 14.69, 14.22; IR (max): 2982, 2226, 1709, 1613, 1548, 1468, 1423, 1356, 1314, 1250, 1122, 1033, 747 cm-1;HRMS: (M+H) calcd for C26H24N3O3426.1818, found 426.1815. Example 28: 4'-((Benzimidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2j) 10 The compound of formula 2j was synthesized according to the general procedure described in example 18 involving corresponding reactant exchange with benzimidazole. The crude material was purified by silica gel column chromatography in hexane: EA (60:40) to provide a white solid with a 79% isolated yield. Melting point:122oC;1H NMR (400 MHz, CDCl3): δ 8.00 (s, 1H), 7.89 – 7.81 (m, 1H), 7.79 – 7.71 (m, 1H), 7.62 (td, J = 7.8, 1.4 Hz, 1H), 7.57 – 7.49 (m, 2H), 7.48 – 7.41 (m, 2H), 7.37 – 7.22 (m, 5H), 5.42 (s, 2H);13C NMR (101 MHz, CDCl3): δ 144.57, 143.95, 143.32, 138.11, 136.24, 133.92, 133.80, 132.99, 130.00, 129.44, 127.89, 127.34, 123.29, 122.43, 120.48, 118.64, 111.16, 110.11, 48.39; IR ( max): 3060, 2924,28961, 2226, 1610, 1491, 1368, 1273, 1197, 1118, 1009, 754, cm-1; HRMS: [M + H]+ calcd for C21H16N3310.1344, found 310.1333. Example 29: 4'-((2-Phenyl benzimidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2k) The compound of formula 2k was synthesized according to the , J = 7.8, 1.0 Hz, 1H), 7.73 – 7.69 (m, 2H), 7.64 (td, J = 7.7, 1.4 Hz, 1H), 7.55 – 7.52 (m, 2H), 7.51 – 7.47 (m, 4H), 7.45 (td, J = 7.6, 1.2 Hz, 1H), 7.34 (ddd, J = 8.1, 5.5, 2.9 Hz, 1H), 7.28 – 7.26 (m, 2H), 7.23 (d, J = 8.5 Hz, 2H), 5.53 (s, 2H);13C NMR (101 MHz, CDCl3): δ 154.22, 144.68, 143.23, 137.72, 137.04, 136.02, 133.86, 132.95, 130.05, 129.50, 129.30, 128.89, 127.81, 126.43, 123.22, 122.84, 120.09, 118.67, 111.20, 110.55, 48.18; IR ( max): 3023, 2924, 2861, 2225, 1574,1450, 1389, 1339, 1214, 1160, 927, 749 cm-1; HRMS (ESI, m / z) [M + H]+ calcd for C27H20N3 386.1630, found 386.1646. ADVANTAGES OF THE INVENTION ^ Present invention relates to developing a continuous photo-flow protocol for formula 1 and formula 2. ^ Present invention relates to a process for an automated solar panel tracker that efficiently follows the direction of sunlight. ^ Developed lab scale and pilot scale solar panel tracker continuous flow platform for bromination reaction. ^ Pilot-scale continuous flow process for the preparation of formula 1 in 5 min residence time with improved yield using NBS and Br2as a brominating reagent. ^ Development of a continuous flow-packed bed reactor platform for the nucleophilic substitution of formula 1a and formula 4 to prepare formula 2. ^ Additional plug-and-play research ultimately enables the photo-flow continuous synthesis of modern small molecule pharmaceuticals, including enantiopure APIs, to fill the future gap for quick manufacturing of the late-stage functionalized biologically active compounds.

Claims

We Claim 1. An artificial intelligence-embedded continuous flow solar tracker system for auto optimization preparation of Angiotensin II receptor blocker intermediate Formula 2 or a pharmaceutically acceptable compounds comprising: a. a plurality of pumps [1] for the continuous flow of reactant connected with the plurality of holders; b. a flow rate controller [1’] to maintain flow rate of the reactant; c. a tubular photo reactor [2] exposed to light with a coiled capillary reactor; d. a cooling system [3] to cool the photo reactor; e. a power supplier [4] to provide a variation of light; f. an In-line IR [5] for analysis purpose; g. an auto collector [6] to collect desired product; h. a central computer system [7] configured to operate the pump [1] flow rate, the photo reactor [2], the power supplier [4], and the auto collector [6]; i. an extractor [9] for inline extraction; and j. a separator [10] to removing inorganic impurities made by hydrophobic membrane has an average pore size of 0.25-0.45 mm. wherein, the outer diameter [OD] of tubular photo reactor [2] is in the range of 1 / 16 to 1 / 2mm, inner diameter [ID] is in the range of 1 mm to 5 mm, length is in the range of 1m to 100 m, and volume is in the range of 1ml to 1000 ml to provide continuous flow with the help of artificial intelligence; wherein for covering the tubular photo reactor [2] with film [8] made from a material allowing the transmittance of blue light selected from glass, perfluoroalkoxy [PFA], polyethylene, polypropylene, nylon and polyetheretherketone (PEEK); wherein, the power supplier [4] to provide a variation of light selected from the blue, green, red, white, high-pressure, low-pressure, medium-pressure Hg lamp thereof.

2. An auto optimization artificial intelligence-based continuous flow process for the preparation of Angiotensin II receptor blocker intermediate (formula 2) by the system as claimed in claim 1,wherein, R1-N-R2 is selecte substituted derivatives of imidazole’s, benzimidazole’s, triazole and carbazole, said process comprising the steps of: (a) pumping a solution of reactants of substituted benzyl bromide (formula 1) (0.1-1 M), and substituted secondary amines (formula 4) (0.1-1 M) in a polar solvent into a stainless-steel cartridge bed reactor [7.0 ml - 1L] filled with base at a temperature in the range of 30 to 100 °C and at a pressure in the range of 1-15 bar; maintaining the reaction mixture in reactor for the time period in the range of 0.6-12.5 minutes yielded the compound of formula 2.

3. The process as claimed in claim 2, wherein the substituted secondary amines formula 4) is selected from the group consisting of 2-butyl-4-chloro-1H-imidazole-5-carbaldehyde (4a), (2- butyl-4-chloro-1H-imidazol-5-yl)methanol (4b), methyl 4-(2-hydroxypropan-2-yl)-2-propyl- 1H-imidazole-5-carboxylate (4c), diethyl 2-propyl-1H-imidazole-4,5-dicarboxylate(4d), 1H- imidazole (4e), 2-methyl-1H-imidazole(4f), 2-phenyl-1H-imidazole(4g), methyl 2-ethoxy- 1H-benzo[d]imidazole-7-carboxylate(4h), ethyl 2-ethoxy-1H-benzo[d]imidazole-7- carboxylate(4i), 1H-benzo[d]imidazole--methane (4j), 2-phenyl-1H-benzo[d]imidazole (4k), 1H-benzo[d]imidazol-2-amine(4l), 1,7'-dimethyl-2'-propyl-1H,3'H-2,5'- bibenzo[d]imidazole(4m), 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one(4n), 1H-1,2,4- triazole(4o), 9H-carbazole--methane(4p).

4. The process as claimed in claim 2, wherein the polar solvent selected from the group consisting of acetone, acetonitrile, dimethylformamide (DMF), dimelthylsulfoxide (DMSO), isopropanol, and methanol and mixtures thereof and base selected from the group consisting of K2CO3, Na2CO3, KOH, and Amberlyst-15 hydroxide.

5. The process as claimed in claim 2, wherein compounds of Angiotensin II receptor blocker intermediate (Formula 2) is selected from the group consisting of from 4'-((2-Butyl-4-chloro-5-formyl-1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (Losartan intermediate) (2a), 4'-((2-Butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl) methyl)-[1,1'-biphenyl]-2- carbonitrile (Losartan intermediate) (2b), Ethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-4- (2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate (Olmesartan intermediate) (2c), Diethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2-propyl-1H-imidazole-4,5- dicarboxylate (Olmesartan intermediate) (2d), 4'-((Imidazol-1-yl) methyl)-[1,1'-biphenyl]-2- carbonitrile (2e), 4'-((2-Methyl imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2f), 4'- ((2-Phenyl imidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2g), Methyl 1-((2'-cyano- [1,1'-biphenyl]-4-yl) methyl)-2-ethoxy benzimidazole-7-carboxylate (candesartan intermediate) (2h), Ethyl 1-((2'-cyano-[1,1'-biphenyl]-4-yl) methyl)-2-ethoxy benzimidazole- 7-carboxylate (candesartan intermediate) (2i), 4'-((Benzimidazol-1-yl) methyl)-[1,1'- biphenyl]-2-carbonitrile (2j), 4'-((2-Phenyl benzimidazol-1-yl) methyl)-[1,1'-biphenyl]-2- carbonitrile (2k), 4'-((2-Amino benzimidazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2l), 4'-((1,7'-Dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl) methyl)-[1,1'- biphenyl]-2-carbonitrile (Telmisartan intermediate) (2m), 4'-((2-butyl-4-oxo-1,3- diazaspiro[4.4]non-1-en-3-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile (Irbesartan precursor) (2n), 4'-((1,2,4-Triazol-1-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2o), 4'-((Carbazol-9-yl) methyl)-[1,1'-biphenyl]-2-carbonitrile (2p).

6. The process as claimed in claim 2, wherein the substituted benzyl bromide [Formula 1] is prepared by bromination reaction of substituted phenylmethane [Formula 3] with N- Bromosuccinimide [NBS] in artificial intelligence-embedded continuous flow solar tracker system as claimed in claim 1 to get compound of formula 1 comprising the step of:- a) pumping a solution of reactants of formula 3 (0.1-1 M), and NBS (0.1-1 M) in a polar aprotic solvent into a PFA tubular photo reactor [2, Figure-1] exposed to light selected from the blue, green, red, white, high-pressure, low-pressure, medium- pressure Hg lamp thereof; b) maintaining the reaction mixture in PFA tubular photo reactor [2, Figure-1] for the time period in the range of 0.6-12.5 minutes under pressure in the range of 1-10 bar; c) inline extraction [9] and separation by separator [10] removing inorganic impuritiesto obtain compound of formula 1.

7. The process as claimed in claim 6, wherein substituted phenylmethane (formula 3) is selected from the group consisting of 1-benzonitrile, chloro, bromo, iodo, methyl, cyano, nitro, bromophenyl and polar aprotic solvent selected from the group consisting of MeCN, dichloromethane, dichloroethane, aromatic hydrocarbons, cyclic hydrocarbons, THF, Ethyl Acetate, and mixtures thereof.

8. The process as claimed in claim 6, wherein represented compound of substituted benzyl bromide (formula 1) is selected from 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile (formula 1a), 1-(bromomethyl)-4-iodobenzene (1b), 1-bromo-4-(bromomethyl)benzene (1c), 1-(bromomethyl)-4-chlorobenzene (1d), 4-(bromomethyl) benzonitrile (1e), 1- (bromomethyl)-4-nitrobenzene (1f), 1-(bromomethyl)-3-iodobenzene (1g), 1-(bromomethyl)- 3-iodo-5-methylbenzene (1h), 1-(bromomethyl)-3,5-dimethylbenzene (1i), 1-(bromomethyl)- 2-iodobenzene (1j), 2-(bromomethyl)benzonitrile (1k), 1-(bromomethyl)-2-nitrobenzene (1l), 2-bromo-1-(bromomethyl)-3-methylbenzene (1m), 1-bromo-2-(bromomethyl)naphthalene (1n), 9-bromo-9H-fluorene (1o).

9. The process as claimed in claim 6, wherein lab scale preparation of substituted benzyl bromide [Formula 1] in artificial intelligence-embedded continuous flow solar tracker system and pilot scale preparation of substituted benzyl bromide [formula 1] with 93-94 % yield in continuous flow process solar tracker system consisting of (figure 7): i. a plurality of holders [1] for holding particular reactant; ii. a plurality of pumps [2] provided for the continuous flow of reactant connected with the plurality of holders; iii. a flow rate controller to maintain flow rate of the reactant; iv. a plurality of syringes [3] to inject the reactants from the holder [1]; v. a solenoid valve [4] coupled with a light-dependent resistor (LDR) micro controller system [5] to control the direction of reagent flow according to the light intensity; vi. a panel reactor [6] includes A solar light source [7], and A reactor tubes [8]; vii. a solar light source [7] displayed at the one end for transporting the reactants [8];viii. a reactor tubes [8] displayed at another end for Product collector [14] to collecting the product; ix. a panel switch [10]; x. a stepper motor speed [12] programmed to track the sun’s trajectory; and xi. a computer program [11] configured to control the stepper motor speed [12], and solar panel reactor [13] movement.

Images